CLINICAL TRIALS CENTER FOR ALLHAT

ALLHAT是一项基于实践的随机临床试验， 抗高血压药物治疗，在一个子集中，胆固醇- 降低治疗。4万名高危高血压患者，年龄 55岁及以上的人，包括很高比例的非洲裔美国人， 招募的因为糖尿病和高血压经常一起发生 糖尿病高血压患者患心血管疾病的几率很高， 招募了高比例的糖尿病患者。主 双盲降压试验的目的是确定 非致命性心肌梗死和 冠心病死亡率较低的患者接受 赖诺普利（ACE抑制剂），钙拮抗剂，或 多沙唑嗪（α-1-阻滞剂）比对照组接受 氯噻酮（利尿剂）。次要终点为总心血管事件 死亡率、主要发病率、全因死亡率和 生活质量血脂试验的主要目的是 确定全因死亡率是否低于中度 高胆固醇血症男性女性患者接受胆固醇- 降低药物普伐他汀（HMG CoA还原酶抑制剂），而不是在开放的 “常规护理”对照组。次要终点是合并的 非致死性心肌梗死和冠心病发病率 死亡率、主要非心血管疾病发病率和死亡率以及健康- 相关的生活质量。平均随访时间将 大约6（4.5 - 7.5）年。 招募患者，而不是使用独立资助的诊所 通过以办公室为基础的做法和高血压诊所， 通过临床试验中心按每位患者报销。 本合同适用于临床试验中心。一些功能 包括协调所有数据收集， 数据存储、与研究相关的分析活动，以及 招募和培训（沿着NHLBI）适当的临床 研究中心和核心实验室需要进行研究。

ALLHAT is a practice-based, randomized clinical trial of antihypertensive pharmacologic treatment and, in a subset, cholesterol- lowering therapy. Forty thousand high-risk hypertensive patients, age 55 and older, including a high percentage of African-Americans are being recruited. Because diabetes and hypertension occur together frequently and diabetic hypertensives have high rates of cardiovascular disease, a high percentage of diabetic patients were recruited. The primary objective of the double-blind antihypertensive trial is to determine whether the combined incidence of nonfatal myocardial infarction and coronary heart disease death is lower among patients receiving lisinopril (ACE inhibitor), amlodipine (calcium antagonist), or doxazosin (alpha-1-blocker) than in a control group receiving chlorthalidone (diuretic). Secondary endpoints are total cardiovascular mortality, major morbidity, all-cause mortality and health-related quality of life. The primary objective of the lipid trial is to determine whether all-cause mortality is lower in moderately hypercholesterolemic men women patients receiving the cholesterol- lowering drug pravastatin (HMG CoA reductase inhibitor), than in an open "usual care" control group. Secondary endpoints are the combined incidence of nonfatal myocardial infarction and coronary heart disease death, major non-cardiovascular morbidity and mortality, and health- related quality of life. The average duration of follow-up will approximately 6 (4.5 - 7.5) years. Rather than using independently funded clinics, patients are recruited through office-based practices and hypertension clinics which are reimbursed through the Clinical Trials Center on a per-patient basis. This contract is for the Clinical Trials Center. Some of the functions of the Clinical Trials Center include coordinating all data collection, storage of data, analysis activities related to the study, and recruiting and training (along with the NHLBI) appropriate clinical sites and core laboratories require to conduct the study.